About ETPNThe European Technology Platform on Nanomedicine
Become a new member of ETPN!
and benefit notably from free registration at ETPN2017
The European Technology Platform on Nanomedicine (ETPN) was established in 2005 as a joint venture of the European Commission and CEOs of large industrial companies, SMEs and academic research institutions to investigate and advance joint activities in the area of nanotechnology in medicine. Since 2005 the ETPN published a number of strategic documents outlining the needs and roadmaps for nanomedicine research in Europe. The ETPN contributed to set up numerous European funded projects providing a first impression of the conditions for a suitable social and economic environment and the structural requirements for an efficient translation of R&D results into innovative nanomedicine. The ETPN supports its members in coordinating their joint research efforts and improving communication amongst the members as well as towards the European Commission and the European Member States.
In 2013, ETPN has published a White Paper “Contribution of Nanomedicine to Horizon 2020” setting the groundwork to manage the efficient translation of nanotechnology from a Key Enabling Technology (KET) into new and innovative medical products. Two years later the concrete implementation of the recommendations formulated in this strategic document started with the launch of the EU-Nano-Characterization Lab, of 3 pilot lines for GMP manufacturing of nanomedicines and well as with the constitution of the Nanomed Translation Advisory Board in the framework of the ENATRANS Coordination and Support Action.
More recently, ETPN has published together with Euronomed2 the update of the Strategic Research & Innovation Agenda for Nanomedicine. The SRIA is intended to provide a framework for the fruitful deployment of innovative Nanomedicine solutions for healthcare and to provide the ecosystem, including European, national and regional public authorities, with roadmaps and priorities for research. It contains precise recommendations for R&D topics on selected diseases that affect a large number of patients (cardio-vascular diseases, cancer, diabetes, neurodegenerative diseases, infection diseases, osteoarticular pathologies and others). Moreover, the focus is set on translability of research results, i.e. their adequacy with clinical but also industrial needs.
In 2015, the ETPN became an independent Association under the French law 1901, with its Secretariat in central Paris, in the campus of the ESPCI (Ecole Supérieure de Physique et Chimie Industrielle de la ville de Paris). The association gathers today more than 120 members from 25 different Member States, covering all stakeholders of Nanomedicine : academia, SMEs, industry, pubic agencies, representatives from national platforms, European Commission, etc. You can become a new member of ETPN right here.